Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Multiple Sclerosis
Interventions
DRUG

Rituximab Infusion

Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.

Trial Locations (1)

27157

Wake Forest Baptist Medical Center, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT02040116 - Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases | Biotech Hunter | Biotech Hunter